Trial Profile
Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 07 Nov 2018 Status changed to discontinued as per PI's request
- 07 May 2018 Status changed from active, no longer recruiting to completed.
- 12 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.